Known targets — ChEMBL curated mechanism
DHFRGARTPTGFRPTGIRPTGS1PTGS2TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8envmurAthyA
The experimentally established mechanism targets of Tromethamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | FDPS | P14324 | 6/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 6/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tromethamine SCHEMBL7899122 | 1.00 | LMNA (0.67) | LMNAMEN1KMT2AFDPSGRM4 | |
| Tromethamine SCHEMBL10930305 | 0.87 | LMNA (0.50) | LMNAMEN1KMT2AFDPSGRM4 | |
| Tromethamine SCHEMBL29366645 | 0.85 | KMT2A (0.56) | LMNAMEN1KMT2AFDPSGRM4 | |
| Tromethamine SCHEMBL7572662 | 0.85 | LMNA (0.56) | LMNAMEN1KMT2AFDPSGRM4 | |
| Tromethamine SCHEMBL29130482 | 0.83 | KMT2A (0.53) | LMNAMEN1KMT2AFDPSGRM4 | |
| Phosphoric Acid SCHEMBL11822162 | 0.83 | LMNA (0.45) | LMNAMEN1KMT2AFDPSGRM4 | |
| Tromethamine SCHEMBL975 | 0.82 | — | — | |
| Tromethamine SCHEMBL3696191 | 0.82 | — | — | |
| Tromethamine SCHEMBL17484 | 0.82 | MEN1 (1.00) | LMNAMEN1KMT2AS1PR1S1PR3 | |
| Tromethamine SCHEMBL2202687 | 0.81 | KMT2A (0.59) | LMNAMEN1KMT2AFDPSS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 261 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119925276-A | CRAC inhibitor freeze-dried powder preparation based on tromethamine phosphate salt prodrug and preparation method thereof | 天津辰欣药物研究有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-117343966-A | Method for producing hydroxyl free radical by oxidase-phthalocyanine supermolecule near infrared enzyme cascade catalysis | 吉林大学 | 2024-01-05 | — | — | CN | claimed |
| CN-115677821-A | Antibacterial peptide and preparation method thereof | 韩玉玲 | 2023-02-03 | — | — | CN | claimed |
| CN-112457372-B | Synthesis method and application of polypeptide hydrazide containing cysteine residues | 华南理工大学 | 2021-09-21 | — | — | CN | claimed |
| CN-110218778-B | PCR reaction system, reagent, kit and PCR method | 珠海宝锐生物科技有限公司 | 2021-05-28 | — | — | CN | claimed |
| CN-112457372-A | Synthesis method and application of polypeptide hydrazide containing cysteine residues | 华南理工大学 | 2021-03-09 | — | — | CN | claimed |
| EP-3684835-A1 | COLOUR-STABLE CURING COMPOSITIONS CONTAINING POLYISOCYANATE (CYCLO)ALIPHATIC DIISOCYANATES | BASF SE (DE) | 2020-07-29 | — | — | EP | claimed |
| EP-3684833-A1 | METHOD FOR PRODUCING POLYISOCYANATES OF (CYCLO)ALIPHATIC DIISOCYANATES WHICH ARE FLOCCULATION-STABLE IN SOLVENTS | BASF SE (DE) | 2020-07-29 | — | — | EP | claimed |
| CN-106574089-B | Polymer composition with low olfactory sensory impression | SABIC环球技术有限责任公司 | 2020-03-03 | — | — | CN | claimed |
| US-20130098775-A1 | Glucose biosensor with improved shelf life | NOVA BIOMEDICAL CORPORATION (US) | 2013-04-25 | — | — | US | claimed |
| WO-2013059534-A1 | GLUCOSE BIOSENSOR WITH IMPROVED SHELF LIFE | NOVA BIOMEDICAL CORPORATION (US) | 2013-04-25 | — | — | WO | claimed |
| EP-0506922-B1 | INDIRECT POTENTIOMETRIC METHOD AND DILUENT FOR ANALYSIS OF LITHIUM | BECKMAN INSTRUMENTS INC (US) | 1996-01-31 | — | — | EP | claimed |
| US-5288678-A | A mixtures of PH buffer and a non-cationic surfactant; medical diagnosis | BECKMAN INSTRUMENTS, INC. (US) | 1994-02-22 | — | — | US | claimed |
| EP-0304151-B1 | Measurement of calcium ions | INSTRUMENTATION LAB SPA (IT) | 1993-12-15 | — | — | EP | claimed |
| EP-0506922-A1 | INDIRECT POTENTIOMETRIC METHOD AND DILUENT FOR ANALYSIS OF LITHIUM. | BECKMAN INSTRUMENTS INC (US) | 1992-10-07 | — | — | EP | claimed |
| US-5110742-A | Quantitative analysis of clinical sample; electrodes selective for lithium and for interfering ion | BECKMAN INSTRUMENTS, INC. (US) | 1992-05-05 | — | — | US | claimed |
| WO-1992007274-A1 | INDIRECT POTENTIOMETRIC METHOD AND DILUENT FOR ANALYSIS OF LITHIUM | BECKMAN INSTRUMENTS, INC. (US) | 1992-04-30 | — | — | WO | claimed |
| US-4870024-A | DILUTION WITH TRIS PHOSPHATE | FISHER SCIENTIFIC COMPANY (US) | 1989-09-26 | — | — | US | claimed |
| EP-0304151-A2 | Measurement of calcium ions | INSTRUMENTATION LABORATORY S.p.A. (IT) | 1989-02-22 | — | — | EP | claimed |
| JP-9154571-A | — | — | None | — | — | JP | disclosed |
| US-20260115287-A1 | T CELL THERAPY IN PATIENTS WHO HAVE HAD PRIOR STEM CELL TRANSPLANT | CELGENE CORPORATION (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4687843-A1 | FORMULATIONS AND USES THEREOF | Sartorius Albumedix Limited (GB) | 2026-02-11 | — | — | EP | disclosed |
| EP-4676233-A1 | ENRICHMENT OF A CASEIN IN A COMPOSITION | NewMilkBuzz B.V (NL) | 2026-01-14 | — | — | EP | disclosed |
| EP-4659809-A2 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250345432-A1 | METHOD FOR PREDICTING RESPONSE TO A T CELL THERAPY | CELGENE CORPORATION (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250295771-A1 | METHODS AND USES RELATED TO T CELL THERAPY AND PRODUCTION OF SAME | CELGENE CORPORATION (US) | 2025-09-25 | — | — | US | disclosed |
| EP-3538539-B1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMA (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250207119-A1 | METHODS AND COMPOSITIONS FOR INHIBITING ADAM10 BIOLOGICAL ACTIVITIES | Verra Therapeutics, Inc. | 2025-06-26 | — | — | US | disclosed |
| US-12297469-B2 | Methods and compositions for inhibiting ADAM10 biological activities | Verra Therapeutics, Inc. (US) | 2025-05-13 | — | — | US | disclosed |
| EP-3828265-B1 | IMPROVED T CELL COMPOSITIONS | 2SEVENTY BIO INC (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-119925276-A | CRAC inhibitor freeze-dried powder preparation based on tromethamine phosphate salt prodrug and preparation method thereof | 天津辰欣药物研究有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119925276-A | CRAC inhibitor freeze-dried powder preparation based on tromethamine phosphate salt prodrug and preparation method thereof | 天津辰欣药物研究有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119925276-A | CRAC inhibitor freeze-dried powder preparation based on tromethamine phosphate salt prodrug and preparation method thereof | 天津辰欣药物研究有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20250123281-A1 | USES OF ANTI-BCMA CHIMERIC ANTIGEN RECEPTORS | CELGENE CORPORATION (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250122276-A1 | ANTIBODIES TO FELINE MCDONOUGH SARCOMA (FMS)-LIKE TYROSINE KINASE 3 RECEPTOR LIGAND (FLT3L) AND USES THEREOF FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-04-17 | — | — | US | disclosed |
| CN-119643849-A | Pre-dyeing protein Marker and preparation method and application thereof | 湖北擎科生物科技有限公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20250064954-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2025-02-27 | — | — | US | disclosed |
| US-12209123-B2 | Antibodies to Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-01-28 | — | — | US | disclosed |
| US-20250026845-A1 | BCMA CHIMERIC ANTIGEN RECEPTORS | 2SEVENTY BIO, INC. | 2025-01-23 | — | — | US | disclosed |
| US-20250009710-A1 | COMPOSITION CONTAINING ARTESUNATE | ZHAO MING (US) | 2025-01-09 | — | — | US | disclosed |
| US-20240342299-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMA (US) | 2024-10-17 | — | — | US | disclosed |
| WO-2024209085-A1 | FORMULATIONS AND USES THEREOF | ALBUMEDIX LTD (GB) | 2024-10-10 | — | — | WO | disclosed |
| EP-4438734-A2 | REPROGRAMMING OF CELLS TO A NEW FATE | The Scripps Research Institute (US) | 2024-10-02 | — | — | EP | disclosed |
| WO-2024188832-A1 | ENRICHMENT OF A CASEIN IN A COMPOSITION | NEWMILKBUZZ B.V (NL) | 2024-09-19 | — | — | WO | disclosed |
| US-12083096-B2 | Composition containing artesunate | ZHAO MING (US) | 2024-09-10 | — | — | US | disclosed |
| US-12060419-B2 | CD79A chimeric antigen receptors | REGENERON PHARMACEUTICALS, INC. (US) | 2024-08-13 | — | — | US | disclosed |
| US-12029784-B2 | BCMA chimeric antigen receptors | 2SEVENTY BIO, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| EP-3399026-B1 | REPROGRAMMING OF CELLS TO A NEW FATE | SCRIPPS RESEARCH INST (US) | 2024-06-26 | — | — | EP | disclosed |
| EP-4365194-A2 | CD79A CHIMERIC ANTIGEN RECEPTORS | 2seventy bio, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| CN-116751812-B | Application of OsABI gene in enhancing nitrogen deficiency stress resistance of rice | 浙江大学海南研究院 | 2024-05-03 | — | — | CN | disclosed |
| CN-117964742-A | Artificial metalloenzyme based on myoglobin scaffold, and chemical synthesis method and application thereof | 华南理工大学 | 2024-05-03 | — | — | CN | disclosed |
| EP-4322991-A1 | T CELL THERAPY IN PATIENTS WHO HAVE HAD PRIOR STEM CELL TRANSPLANT | CELGENE CORPORATION (US) | 2024-02-21 | — | — | EP | disclosed |
| EP-3806903-B1 | CD79A CHIMERIC ANTIGEN RECEPTORS | 2SEVENTY BIO INC (US) | 2024-02-14 | — | — | EP | disclosed |
| CN-117343966-A | Method for producing hydroxyl free radical by oxidase-phthalocyanine supermolecule near infrared enzyme cascade catalysis | 吉林大学 | 2024-01-05 | — | — | CN | disclosed |
| US-20230407401-A1 | DNA DAMAGE DEPENDENT MICRORNA SIGNATURE FOR CANCERS, METHODS AND USES RELATED THERETO | NATIONAL INSTITUTE OF IMMUNOLOGY (IN) | 2023-12-21 | — | — | US | disclosed |
| US-20230398149-A1 | CAR T CELL THERAPY IN PATIENTS WHO HAVE HAD PRIOR ANTI-CANCER ALKYLATOR THERAPY | CELGENE CORPORATION (US) | 2023-12-14 | — | — | US | disclosed |
| CN-117159794-A | Antibacterial titanium-based material, preparation method and application thereof | 广东中科安齿生物科技有限公司 | 2023-12-05 | — | — | CN | disclosed |
| WO-2023230548-A1 | METHOD FOR PREDICTING RESPONSE TO A T CELL THERAPY | CELGENE CORPORATION (US) | 2023-11-30 | — | — | WO | disclosed |
| EP-4272002-A1 | USES OF CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES IN COMBINATION WITH INHIBITORS OF INFLAMMATION-RELATED SOLUBLE FACTORS | Celgene Corporation (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-3686285-B1 | ULTRA-SENSITIVE CHEMILUMINESCENT SUBSTRATES FOR PEROXIDASE | CYANAGEN S R L (IT) | 2023-10-11 | — | — | EP | disclosed |
| US-11761964-B2 | Ultra-sensitive chemiluminescent substrates for peroxidase | CYANAGEN S.R.L. (IT) | 2023-09-19 | — | — | US | disclosed |
| EP-4241278-A2 | CAR T CELL THERAPY IN PATIENTS WHO HAVE HAD PRIOR ANTI-CANCER ALKYLATOR THERAPY | Celgene Corporation (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-4223269-A2 | USES OF ANTI-BCMA CHIMERIC ANTIGEN RECEPTORS | Celgene Corporation (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20230203468-A1 | METHODS AND COMPOSITIONS FOR INHIBITING ADAM10 BIOLOGICAL ACTIVITIES | Verra Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-20230193202-A1 | METHODS FOR MAKING T CELL COMPOSITIONS | 2SEVENTY BIO, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| CN-113768870-B | Artesunate-containing composition and application thereof | 赵鸣 | 2023-06-20 | — | — | CN | disclosed |
| US-11633463-B2 | BCMA chimeric antigen receptors | 2SEVENTY BIO, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| CN-115920018-A | Tumor polypeptide vaccine for treating breast cancer and preparation method thereof | 张腾飞 | 2023-04-07 | — | — | CN | disclosed |
| EP-4143237-A1 | KRAS SPECIFIC ANTIBODIES AND USES THEREOF | Genentech, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230056815-A1 | ANTIBODIES TO FELINE MCDONOUGH SARCOMA (FMS)-LIKE TYROSINE KINASE 3 RECEPTOR LIGAND (FLT3L) AND USES THEREOF FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES | VIELA BIO, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| CN-115677821-A | Antibacterial peptide and preparation method thereof | 韩玉玲 | 2023-02-03 | — | — | CN | disclosed |
| US-11560547-B2 | Methods of making T cell compositions | 2SEVENTY BIO, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| CN-115461375-A | KRAS-specific antibodies and uses thereof | 基因泰克公司 | 2022-12-09 | — | — | CN | disclosed |
| WO-2022221737-A9 | T CELL THERAPY IN PATIENTS WHO HAVE HAD PRIOR STEM CELL TRANSPLANT | JUNO THERAPEUTICS, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| US-11512127-B2 | Antibodies to Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases | VIELA BIO, INC. (US) | 2022-11-29 | — | — | US | disclosed |
| US-11479755-B2 | T cell compositions | 2SEVENTY BIO, INC. (US) | 2022-10-25 | — | — | US | disclosed |
| WO-2022221737-A1 | T CELL THERAPY IN PATIENTS WHO HAVE HAD PRIOR STEM CELL TRANSPLANT | JUNO THERAPEUTICS, INC. (US) | 2022-10-20 | — | — | WO | disclosed |
| CN-111825838-B | Polyester amide and preparation method thereof and fiber | 上海凯赛生物技术股份有限公司 | 2022-10-11 | — | — | CN | disclosed |
| EP-4054622-A1 | USES OF ANTI-BCMA CHIMERIC ANTIGEN RECEPTORS | Celgene Corporation (US) | 2022-09-14 | — | — | EP | disclosed |
| US-20220273613-A1 | COMPOSITION CONTAINING ARTESUNATE | ZHAO MING (US) | 2022-09-01 | — | — | US | disclosed |
| US-20220226374-A1 | CD79B CHIMERIC ANTIGEN RECEPTORS | 2seventy bio, Inc (US) | 2022-07-21 | — | — | US | disclosed |
| US-11382965-B2 | BCMA chimeric antigen receptors | 2SEVENTY BIO, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| EP-4014996-A1 | ANTI-SIALYL TN CHIMERIC ANTIGEN RECEPTORS | Helixmith Co., Ltd (KR) | 2022-06-22 | — | — | EP | disclosed |
| WO-2022120160-A1 | USES OF CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES IN COMBINATION WITH INHIBITORS OF INFLAMMATION-RELATED SOLUBLE FACTORS | CELGENE CORPORATION (US) | 2022-06-09 | — | — | WO | disclosed |
| US-11351236-B2 | BCMA chimeric antigen receptors | 2SEVENTY BIO, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| WO-2022098685-A2 | CAR T CELL THERAPY IN PATIENTS WHO HAVE HAD PRIOR ANTI-CANCER ALKYLATOR THERAPY | CELGENE CORPORATION (US) | 2022-05-12 | — | — | WO | disclosed |
| CN-111978351-B | Fire retardant cage-shaped organic silicon phosphoramide compound and preparation method thereof | 苏州科技大学 | 2022-04-26 | — | — | CN | disclosed |
| CN-111978351-B | Fire retardant cage-shaped organic silicon phosphoramide compound and preparation method thereof | 苏州科技大学 | 2022-04-26 | — | — | CN | disclosed |
| US-20220112308-A1 | KRAS SPECIFIC ANTIBODIES AND USES THEREOF | GENENTECH, INC. (US) | 2022-04-14 | — | — | US | disclosed |
| EP-3971210-A1 | COMPOSITION FOR USE IN THE TREATMENT OF B CELL RELATED CONDITIONS IN A SUBJECT IN NEED THEREOF COMPRISINE AN EFFECTOR CELL COMRISING A BCMA CHIMERIC ANTIGEN RECEPTORS | 2seventy bio, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| US-11279769-B2 | Anti-Sialyl Tn chimeric antigen receptors | HELIXMITH CO., LTD (KR) | 2022-03-22 | — | — | US | disclosed |
| US-11279762-B2 | Idiotypic antibodies against anti-PD-L1 antibodies and uses thereof | GENENTECH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| CN-114133635-A | Oxidation and corrosion resistant plastic | 江苏爱唯生物科技有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-113768870-A | Artesunate-containing composition | 赵鸣 | 2021-12-10 | — | — | CN | disclosed |
| CN-113736298-A | Algae inhibiting material and application thereof in agricultural greenhouse film | 四川大学 | 2021-12-03 | — | — | CN | disclosed |
| CN-109152763-B | Artesunate-containing composition | 赵鸣 | 2021-10-01 | — | — | CN | disclosed |
| CN-107951835-B | Enalapril maleate preparation and application thereof | 湖南千金湘江药业股份有限公司 | 2021-08-24 | — | — | CN | disclosed |
| CN-110218778-B | PCR reaction system, reagent, kit and PCR method | 珠海宝锐生物科技有限公司 | 2021-05-28 | — | — | CN | disclosed |
| CN-112805351-A | Compositions comprising 1, 2-dichloro-1, 2-difluoroethylene for use in heat transfer applications | 科慕埃弗西有限公司 | 2021-05-14 | — | — | CN | disclosed |
| CN-110229189-B | Preparation method of tri-oxalic acid phosphate | 上海如鲲新材料有限公司 | 2021-05-07 | — | — | CN | disclosed |
| US-10987338-B2 | Composition containing artesunate | ZHAO MING (US) | 2021-04-27 | — | — | US | disclosed |
| CN-112661791-A | Preparation method of lithium difluorobis (oxalate) phosphate | 多氟多化工股份有限公司 | 2021-04-16 | — | — | CN | disclosed |
| CN-111978351-A | Fire retardant cage-shaped organic silicon phosphoramide compound and preparation method thereof | 苏州科技大学 | 2020-11-24 | — | — | CN | disclosed |
| CN-111978351-A | Fire retardant cage-shaped organic silicon phosphoramide compound and preparation method thereof | 苏州科技大学 | 2020-11-24 | — | — | CN | disclosed |
| CN-111925390-A | Preparation method of tris (butoxyethyl) phosphate | 太仓康源化建医药有限公司 | 2020-11-13 | — | — | CN | disclosed |
| EP-3684835-A1 | COLOUR-STABLE CURING COMPOSITIONS CONTAINING POLYISOCYANATE (CYCLO)ALIPHATIC DIISOCYANATES | BASF SE (DE) | 2020-07-29 | — | — | EP | disclosed |
| EP-3684833-A1 | METHOD FOR PRODUCING POLYISOCYANATES OF (CYCLO)ALIPHATIC DIISOCYANATES WHICH ARE FLOCCULATION-STABLE IN SOLVENTS | BASF SE (DE) | 2020-07-29 | — | — | EP | disclosed |
| US-10471042-B2 | Composition containing artesunate | ZHAO MING (US) | 2019-11-12 | — | — | US | disclosed |
| CN-110218778-A | PCR reaction system, reagent, kit and PCR method | 珠海宝锐生物科技有限公司 | 2019-09-10 | — | — | CN | disclosed |
| CN-109608497-A | A kind of preparation method of fosfomycin trometamol | 科大华采(武汉)生物科技股份有限公司 | 2019-04-12 | — | — | CN | disclosed |
| US-20190029996-A1 | composition containing artesunate | ZHAO MING (US) | 2019-01-31 | — | — | US | disclosed |
| EP-3402479-A1 | COMPOSITION CONTAINING ARTESUNATE | Zhao, Ming (US) | 2018-11-21 | — | — | EP | disclosed |
| US-9840535-B2 | Method of recovering peptide and method of detecting peptide | SYSMEX CORPORATION (JP) | 2017-12-12 | — | — | US | disclosed |
| WO-2017124045-A1 | COMPOSITION CONTAINING ARTESUNATE | ZHAO MING (US) | 2017-07-20 | — | — | WO | disclosed |
| US-9624263-B2 | Method of recovering peptide and method of detecting peptide | SYSMEX CORPORATION (JP) | 2017-04-18 | — | — | US | disclosed |
| US-9620354-B2 | Method for manufacturing semiconductor substrate with diffusion agent composition | TOKYO OHKA KOGYO CO., LTD. (JP) | 2017-04-11 | — | — | US | disclosed |
| US-20160314975-A1 | DIFFUSION AGENT COMPOSITION | TOKYO OHKA KOGYO CO., LTD. (JP) | 2016-10-27 | — | — | US | disclosed |
| EP-2902407-B1 | Method of recovering peptide | SYSMEX CORP (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-20160099149-A1 | METHOD FOR MANUFACTURING SEMICONDUCTOR SUBSTRATE | TOKYO OHKA KOGYO CO., LTD. (JP) | 2016-04-07 | — | — | US | disclosed |
| EP-2902408-B1 | Method of recovering peptide | SYSMEX CORP (JP) | 2016-04-06 | — | — | EP | disclosed |
| CN-105008343-A | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders | NOVARTIS AG | 2015-10-28 | — | — | CN | disclosed |
| CN-103189361-B | Estrogenic agents and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2015-09-30 | — | — | CN | disclosed |
| CN-104086592-B | A kind of preparation method of fosfomycin trometamol | GUILIN HUAXIN PHARMACEUTICAL Co.,Ltd. (CN) | 2015-09-09 | — | — | CN | disclosed |
| EP-2902407-A1 | Method of recovering peptide | SYSMEX CORPORATION (JP) | 2015-08-05 | — | — | EP | disclosed |
| EP-2902408-A1 | Method of recovering peptide | SYSMEX CORPORATION (JP) | 2015-08-05 | — | — | EP | disclosed |
| US-20150210736-A1 | METHOD OF RECOVERING PEPTIDE AND METHOD OF DETETING PEPTIDE | SYSMEX CORPORATION (JP) | 2015-07-30 | — | — | US | disclosed |
| US-20150203533-A1 | METHOD OF RECOVERING PEPTIDE AND METHOD OF DETECTING PEPTIDE | SYSMEX CORPORATION (JP) | 2015-07-23 | — | — | US | disclosed |
| CN-102807586-B | Preparation method of fosfomycin amine salt | NORTHEAST PHARMACEUTICAL GROUP CO LTD | 2015-05-13 | — | — | CN | disclosed |
| CN-104220426-A | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC | 2014-12-17 | — | — | CN | disclosed |
| CN-101663295-B | Aminopyrimidines useful as inhibitors of protein kinases | VERTEX PHARMA | 2014-11-05 | — | — | CN | disclosed |
| CN-104114551-A | Fluorinated estrogen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS INC | 2014-10-22 | — | — | CN | disclosed |
| CN-104086592-A | Preparation method of fosfomycin tromethamine | GUILIN HUAXIN PHARMACEUTICAL CO LTD | 2014-10-08 | — | — | CN | disclosed |
| CN-102838664-B | Gamma-aminobutyric acid transportprotein as well as coding gene and application of gamma-aminobutyric acid transportprotein | CHINESE ACAD INST MICROBIOLOGY | 2014-06-04 | — | — | CN | disclosed |
| CN-103842563-A | Method of protein display | AFFINITY BIOSCIENCES PTY LTD | 2014-06-04 | — | — | CN | disclosed |
| CN-103724322-A | Androgen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS INC | 2014-04-16 | — | — | CN | disclosed |
| CN-102321556-B | Aeromonas and application of aeromonas in biotransformation of (R)-alpha-hydroxyphenylacetic acid | UNIV JIMEI | 2013-11-27 | — | — | CN | disclosed |
| CN-101790532-B | Preparation method of 5-fluoro-1H-pyrazolo [3,4-b ] pyridine-3-amine and derivatives thereof | VERTEX PHARMA | 2013-11-20 | — | — | CN | disclosed |
| CN-101668760-B | Aminopyrimidines useful as inhibitors of protein kinases | VERTEX PHARMA | 2013-07-24 | — | — | CN | disclosed |
| CN-103189361-A | Estrogen receptor modulators and use thereof | ARAGON PHARMACEUTICALS INC | 2013-07-03 | — | — | CN | disclosed |
| CN-103145702-A | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMA | 2013-06-12 | — | — | CN | disclosed |
| US-20130098775-A1 | Glucose biosensor with improved shelf life | NOVA BIOMEDICAL CORPORATION (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2013059534-A1 | GLUCOSE BIOSENSOR WITH IMPROVED SHELF LIFE | NOVA BIOMEDICAL CORPORATION (US) | 2013-04-25 | — | — | WO | disclosed |
| CN-101316597-B | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMA | 2013-04-17 | — | — | CN | disclosed |
| CN-102939287-A | Estrogen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS INC | 2013-02-20 | — | — | CN | disclosed |
| CN-102884057-A | Androgen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS INC | 2013-01-16 | — | — | CN | disclosed |
| CN-101316843-B | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMA | 2013-01-02 | — | — | CN | disclosed |
| CN-102838664-A | Gamma-aminobutyric acid transportprotein as well as coding gene and application of gamma-aminobutyric acid transportprotein | CHINESE ACAD INST MICROBIOLOGY | 2012-12-26 | — | — | CN | disclosed |
| CN-101098872-B | Pyrrolopyrazines and pyrazolopyrazines useful as protein kinase inhibitors | VERTEX PHARMA | 2012-09-05 | — | — | CN | disclosed |
| CN-101460466-B | Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases | VERTEX PHARMA | 2012-06-13 | — | — | CN | disclosed |
| CN-102399275-A | Gamma-aminobutyric acid transport protein and coding gene and application thereof | CHINESE ACAD INST MICROBIOLOGY | 2012-04-04 | — | — | CN | disclosed |
| CN-102321556-A | Aeromonas and application of aeromonas in biotransformation of (R)-alpha-hydroxyphenylacetic acid | UNIV JIMEI | 2012-01-18 | — | — | CN | disclosed |
| CN-102300862-A | Compounds useful as inhibitors of ATR kinase | — | 2011-12-28 | — | — | CN | disclosed |
| CN-102296053-A | 7-xylosyltaxonoglycosyl hydrolase, nucleotide sequence of gene thereof, and application thereof | — | 2011-12-28 | — | — | CN | disclosed |
| CN-1934113-B | Compositions useful as protein kinase inhibitors | VERTEX PHARMA CO LTD | 2011-11-09 | — | — | CN | disclosed |
| US-8003076-B2 | Methods for conducting metabolic analyses | TARGET DISCOVERY, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| CN-101094853-B | Pyrazolo [1,5-a ] pyrimidines useful as protein kinase inhibitors | VERTEX PHARMA CO LTD | 2011-07-13 | — | — | CN | disclosed |
| EP-2293056-A2 | A method for analysing a metabolic pathway | Target Discovery, Inc. (US) | 2011-03-09 | — | — | EP | disclosed |
| CN-101932583-A | Pyrazolo [1,5-a] pyrimidines useful as jak2 inhibitors | VERTEX PHARMA | 2010-12-29 | — | — | CN | disclosed |
| CN-1812973-B | Indazole compounds useful as protein kinase inhibitors | VERTEX PHARMA CO LTD | 2010-12-22 | — | — | CN | disclosed |
| CN-101848909-A | Pyrrolo [3,2-C ] pyridines useful as protein kinase inhibitors | VERTEX PHARMA | 2010-09-29 | — | — | CN | disclosed |
| CN-101824043-A | The composition that can be used as kinases inhibitor | VERTEX PHARMA | 2010-09-08 | — | — | CN | disclosed |
| CN-101790532-A | Preparation method of 5-fluoro-1H-pyrazolo [3,4-b ] pyridine-3-amine and derivatives thereof | VERTEX PHARMA | 2010-07-28 | — | — | CN | disclosed |
| CN-1894258-B | Compositions useful as protein kinase inhibitors | VERTEX PHARMA CO LTD | 2010-06-16 | — | — | CN | disclosed |
| CN-101668760-A | Aminopyrimidines useful as inhibitors of protein kinases | VERTEX PHARMA | 2010-03-10 | — | — | CN | disclosed |
| CN-101646671-A | Compound as kinases inhibitor | VERTEX PHARMA US | 2010-02-10 | — | — | CN | disclosed |
| CN-100567247-C | A kind of method that adopts membrane separation technique to prepare amygdalic acid | UNIV FUZHOU (CN) | 2009-12-09 | — | — | CN | disclosed |
| CN-101589036-A | Aminopyrimidines useful as inhibitors of protein kinases | VERTEX PHARMA (US) | 2009-11-25 | — | — | CN | disclosed |
| CN-101573365-A | Compounds useful as inhibitors of protein kinases | VERTEX PHARMA (US) | 2009-11-04 | — | — | CN | disclosed |
| CN-101568535-A | Aminopyridines and aminopyrimidines useful as protein kinase inhibitors | VERTEX PHARMA (US) | 2009-10-28 | — | — | CN | disclosed |
| US-7572303-B2 | A symmetrical dialkyl carbonate, a metal, borong, silicon, or group 7 compound, a hydrogen or hydrocarbon-based fuel, an oxidizer, and a metallic cocatalyst; minimized hydrolysis; improved combustion and storage stability | OCTANE INTERNATIONAL, LTD. (US) | 2009-08-11 | — | — | US | disclosed |
| CN-101495474-A | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMA (US) | 2009-07-29 | — | — | CN | disclosed |
| CN-101484447-A | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMA (US) | 2009-07-15 | — | — | CN | disclosed |
| CN-100500636-C | Method of extracting amygdalic acid using strong alkali anion exchange resin | UNIV FUZHOU (CN) | 2009-06-17 | — | — | CN | disclosed |
| CN-101460466-A | Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases | VERTEX PHARMA (US) | 2009-06-17 | — | — | CN | disclosed |
| CN-101400678-A | Thiophene amides useful as protein kinase inhibitors | VERTEX PHARMA (US) | 2009-04-01 | — | — | CN | disclosed |
| CN-101358980-A | Homotype cysteine detecting method | BEIJING STRONG BIOTECHNOLOGIES (CN) | 2009-02-04 | — | — | CN | disclosed |
| US-20090010915-A1 | Methods for Conducting Metabolic Analyses | TARGET DISCOVERY, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| CN-101321530-A | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMA (US) | 2008-12-10 | — | — | CN | disclosed |
| CN-101316597-A | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMA (US) | 2008-12-03 | — | — | CN | disclosed |
| CN-101316843-A | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMA (US) | 2008-12-03 | — | — | CN | disclosed |
| CN-100434413-C | Method for separating and purifying mandelic acid using wealk alkali anion exchange agent | UNIV FUZHOU (CN) | 2008-11-19 | — | — | CN | disclosed |
| US-7435406-B2 | Methods for conducting metabolic analyses | TARGET DISCOVERY, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| CN-101228160-A | Azaindoles useful as inhibitors of protein kinases | VERTEX PHARMA (US) | 2008-07-23 | — | — | CN | disclosed |
| CN-100393691-C | Method for preparing mandelic acid by macroporous adsorptive resin | UNIV FUZHOU (CN) | 2008-06-11 | — | — | CN | disclosed |
| EP-1194768-A4 | POLYPEPTIDE FINGERPRINTING METHODS, METABOLIC PROFILING, AND BIOINFORMATICS DATABASE | TARGET DISCOVERY INC (US) | 2008-03-26 | — | — | EP | disclosed |
| CN-101111479-A | Pyridones useful as kinase inhibitors | VERTEX PHARMA (US) | 2008-01-23 | — | — | CN | disclosed |
| CN-101098872-A | Pyrrolopyrazines and pyrazolopyrazines useful as protein kinase inhibitors | VERTEX PHARMA (US) | 2008-01-02 | — | — | CN | disclosed |
| CN-101094853-A | Pyrazolo [1, 5-a ] pyrimidines useful as protein kinase inhibitors | VERTEX PHARMA (US) | 2007-12-26 | — | — | CN | disclosed |
| CN-100351251-C | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2007-11-28 | — | — | CN | disclosed |
| CN-1958551-A | Method for preparing mandelic acid by using membrane isolation technique | UNIV FUZHOU (CN) | 2007-05-09 | — | — | CN | disclosed |
| US-7211376-B2 | Polypeptide fingerprinting methods | TARGET DISCOVERY, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| CN-1948262-A | Method of extracting amygdalic acid using strong alkali anion exchange resin | UNIV FUZHOU (CN) | 2007-04-18 | — | — | CN | disclosed |
| CN-1944382-A | Method for separating and purifying mandelic acid using wealk alkali anion exchange agent | UNIV FUZHOU (CN) | 2007-04-11 | — | — | CN | disclosed |
| CN-1934113-A | Compositions useful as protein kinase inhibitors | VERTEX PHARMA (US) | 2007-03-21 | — | — | CN | disclosed |
| CN-1894258-A | Compositions useful as protein kinase inhibitors | VERTEX PHARMA (US) | 2007-01-10 | — | — | CN | disclosed |
| CN-1262662-C | Chimeric expression promoters originating from commelina yellow mottle virus and cassava vein mosaic virus | MERISTEM THERAPEUTICS (FR) | 2006-07-05 | — | — | CN | disclosed |
| EP-0954558-B1 | FUEL COMPOSITIONS EXHIBITING IMPROVED FUEL STABILITY | ORR WILLIAM C (US) | 2006-06-14 | — | — | EP | disclosed |
| CN-1214103-C | Detection of micro-organisms | FLUID TECHNOLOGIES LTD (GB) | 2005-08-10 | — | — | CN | disclosed |
| US-20050153346-A1 | Methods for conducting metabolic analyses | TARGET DISCOVERY, INC. (US) | 2005-07-14 | — | — | US | disclosed |
| CN-1639153-A | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2005-07-13 | — | — | CN | disclosed |
| US-20050089930-A1 | Polypeptide fingerprinting methods | TARGET DISCOVERY, INC. (US) | 2005-04-28 | — | — | US | disclosed |
| US-20050075282-A1 | Materials and methods for inhibiting the development of epilepsy | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-04-07 | — | — | US | disclosed |
| US-20050044778-A1 | Fuel compositions employing catalyst combustion structure | OCTANE INTERNATIONAL, LTD. | 2005-03-03 | — | — | US | disclosed |
| CN-1190431-C | Production method of (per-rac) alpha tocopherol | DSM IP N V (NL) | 2005-02-23 | — | — | CN | disclosed |
| US-6849396-B2 | Determining metabolic flux values for target analytes by monitoring relative isotope abundance of stable isotope in substrate labeled with stable isotope and one or more target metabolites formed through metabolism of labeled substrate | TARGET DISCOVERY, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| CN-1570135-A | Homotype cysteine detecting method adopting micromolecule trapping technology | BEIJING JIUQIANG BIOTECHNOLOGY (CN) | 2005-01-26 | — | — | CN | disclosed |
| US-20040262160-A1 | Protein separation by electrophoresis | TARGET DISCOVERY, INC. | 2004-12-30 | — | — | US | disclosed |
| US-20040237384-A1 | Fuel compositions exhibiting improved fuel stability | OCTANE INTERNATIONAL, LTD. | 2004-12-02 | — | — | US | disclosed |
| US-6818112-B2 | CONTROLLED DISTILLATION; RESOLUTION | TARGET DISCOVERY, INC. | 2004-11-16 | — | — | US | disclosed |
| CN-1523112-A | Tetracycline-regulated transcriptional modulators | BASF | 2004-08-25 | — | — | CN | disclosed |
| US-6764817-B1 | CAN BE USED FOR DRUG SCREENING, DISEASE LABELS, IDENTIFYING DRUG TARGETS | TARGET DISCOVERY, INC. | 2004-07-20 | — | — | US | disclosed |
| US-20040091943-A1 | Methods for conducting metabolic analyses | TARGET DISCOVERY, INC. | 2004-05-13 | — | — | US | disclosed |
| US-6677114-B1 | HIGH RESOLUTION, PRECISION AND SENSITIVITY PROTEOMICS; MULTIDIMENSIONAL CAPILLARY ELECTROPHORESIS, MASS SPECTRO-GRAPHIC FRAGMENTATION AND PROTEIN SEQUENCE TAG IDENTIFICATION | TARGET DISCOVERY, INC. | 2004-01-13 | — | — | US | disclosed |
| US-6652608-B1 | Fuel compositions exhibiting improved fuel stability | OCTANE INTERNATIONAL, LTD. | 2003-11-25 | — | — | US | disclosed |
| US-20030106797-A1 | Protein separation via multidimensional electrophoresis | TARGET DISCOVERY, INC. (US) | 2003-06-12 | — | — | US | disclosed |
| US-6537432-B1 | Series of separations including at least one of capillary isoelectric focusing or zone electrophoresis; utilizing controlled fractionation and labeling techniques | TARGET DISCOVERY, INC. | 2003-03-25 | — | — | US | disclosed |
| CN-1369003-A | Detection of microorganisms | FSM TECHNOLOGIES LTD (GB) | 2002-09-11 | — | — | CN | disclosed |
| CN-1365977-A | Production method of (per-rac) alpha tocopherol | ROCHE VITAMIN AG (CH) | 2002-08-28 | — | — | CN | disclosed |
| CN-1353763-A | Chimeric expression promoter derived from dayflower yellow mottle virus and cassava vein mosaic virus | MERISTEM THERAPEUTICS (FR) | 2002-06-12 | — | — | CN | disclosed |
| CN-1351669-A | Chimeric promoter based on pea plastocyanin PETE promoter | MERISTEM THERAPEUTICS (FR) | 2002-05-29 | — | — | CN | disclosed |
| EP-1194768-A1 | POLYPEPTIDE FINGERPRINTING METHODS, METABOLIC PROFILING, AND BIOINFORMATICS DATABASE | Target Discovery, Inc. (US) | 2002-04-10 | — | — | EP | disclosed |
| CN-1339067-A | Synthetic and chimeric promoters, expresion cassettes, plasmids, vectors, transgenic plants and seeds containing them, and method for producing them | MERISTEM THERAPEUTICS (FR) | 2002-03-06 | — | — | CN | disclosed |
| US-6212418-B1 | Methods, kits, electrodes and compositions for assessing the level of an analyte of interest in fluid samples | ADVANCED MONITORING SYSTEMS LTD. (IL) | 2001-04-03 | — | — | US | disclosed |
| EP-1051461-A2 | FUEL COMPOSITIONS EMPLOYING CATALYST COMBUSTION STRUCTURE | ORR, William C. (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-2000063683-A1 | POLYPEPTIDE FINGERPRINTING METHODS, METABOLIC PROFILING, AND BIOINFORMATICS DATABASE | TARGET DISCOVERY, INC. (US) | 2000-10-26 | — | — | WO | disclosed |
| EP-1032303-A1 | METHODS, KITS, ELECTRODES AND COMPOSITIONS FOR ASSESSING THE LEVEL OF AN ANALYTE OF INTEREST IN FLUID SAMPLES | AMS- Advanced Monitoring Systems Ltd. (IL) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999066009-A2 | FUEL COMPOSITIONS EMPLOYING CATALYST COMBUSTION STRUCTURE | ORR WILLIAM C (US) | 1999-12-23 | — | — | WO | disclosed |
| EP-0954558-A1 | FUEL COMPOSITIONS EXHIBITING IMPROVED FUEL STABILITY | ORR, William C. (US) | 1999-11-10 | — | — | EP | disclosed |
| CN-1228125-A | Universal test systems and method for identifying multiple families of microorganisms | DADE MICROSCAN INC (US) | 1999-09-08 | — | — | CN | disclosed |
| EP-0503297-B1 | GLIA activating factor and its production | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-07-14 | — | — | EP | disclosed |
| WO-1999026533-A1 | METHODS, KITS, ELECTRODES AND COMPOSITIONS FOR ASSESSING THE LEVEL OF AN ANALYTE OF INTEREST IN FLUID SAMPLES | AMS - ADVANCED MONITORING SYSTEMS LTD. (IL) | 1999-06-03 | — | — | WO | disclosed |
| CN-1215994-A | Rnase L activators and antisense oligonucleotides effective to treat RSV infections | NAT INST HEALTH (US) | 1999-05-05 | — | — | CN | disclosed |
| WO-1998026028-A1 | FUEL COMPOSITIONS EXHIBITING IMPROVED FUEL STABILITY | ORR WILLIAM C (US) | 1998-06-18 | — | — | WO | disclosed |
| CN-1167504-A | Tetracycline-regulated transcriptional modulators | BASF AG (DE) | 1997-12-10 | — | — | CN | disclosed |
| EP-0504380-B1 | METHOD FOR DETERMINATION OF TOTAL CALCIUM EMPLOYING A DILUENT | BECKMAN INSTRUMENTS INC (US) | 1997-11-12 | — | — | EP | disclosed |
| JP-H09154571-A | SERUM-FREE CULTURE MEDIUM FOR PRODUCING VIRUS | KURABO IND LTD | 1997-06-17 | — | — | JP | disclosed |
| US-5622928-A | POLYPEPTIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-04-22 | — | — | US | disclosed |
| EP-0515089-B1 | Ink compositions having decreased drying times | XEROX CORP (US) | 1996-11-13 | — | — | EP | disclosed |
| US-5512460-A | POLYPEPTIDES | TAKEDA CHEMICAL INDUSTRIES, LDT (JP) | 1996-04-30 | — | — | US | disclosed |
| CN-1119457-A | Bone stimulating factor | OSTEOPHARM LTD (CA) | 1996-03-27 | — | — | CN | disclosed |
| EP-0506922-B1 | INDIRECT POTENTIOMETRIC METHOD AND DILUENT FOR ANALYSIS OF LITHIUM | BECKMAN INSTRUMENTS INC (US) | 1996-01-31 | — | — | EP | disclosed |
| US-5288678-A | A mixtures of PH buffer and a non-cationic surfactant; medical diagnosis | BECKMAN INSTRUMENTS, INC. (US) | 1994-02-22 | — | — | US | disclosed |
| US-5288678-A | A mixtures of PH buffer and a non-cationic surfactant; medical diagnosis | BECKMAN INSTRUMENTS, INC. (US) | 1994-02-22 | — | — | US | disclosed |
| EP-0304151-B1 | Measurement of calcium ions | INSTRUMENTATION LAB SPA (IT) | 1993-12-15 | — | — | EP | disclosed |
| EP-0515089-A1 | Ink compositions having decreased drying times | XEROX CORPORATION (US) | 1992-11-25 | — | — | EP | disclosed |
| EP-0506922-A1 | INDIRECT POTENTIOMETRIC METHOD AND DILUENT FOR ANALYSIS OF LITHIUM. | BECKMAN INSTRUMENTS INC (US) | 1992-10-07 | — | — | EP | disclosed |
| EP-0503297-A1 | GLIA activating factor and its production | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-09-16 | — | — | EP | disclosed |
| US-5110742-A | Quantitative analysis of clinical sample; electrodes selective for lithium and for interfering ion | BECKMAN INSTRUMENTS, INC. (US) | 1992-05-05 | — | — | US | disclosed |
| US-5110742-A | Quantitative analysis of clinical sample; electrodes selective for lithium and for interfering ion | BECKMAN INSTRUMENTS, INC. (US) | 1992-05-05 | — | — | US | disclosed |
| WO-1992007274-A1 | INDIRECT POTENTIOMETRIC METHOD AND DILUENT FOR ANALYSIS OF LITHIUM | BECKMAN INSTRUMENTS, INC. (US) | 1992-04-30 | — | — | WO | disclosed |
| WO-1992007274-A1 | INDIRECT POTENTIOMETRIC METHOD AND DILUENT FOR ANALYSIS OF LITHIUM | BECKMAN INSTRUMENTS, INC. (US) | 1992-04-30 | — | — | WO | disclosed |
| US-5100469-A | Colorant, carrier and meso-erythritol or a trihydroxy compound | XEROX CORPORATION (US) | 1992-03-31 | — | — | US | disclosed |
| US-5059522-A | Releasing selected enzymes and exposing them to a panel of immobilized dots of specific antibodies, observing binding | WAYNE LAWRENCE G (US) | 1991-10-22 | — | — | US | disclosed |
| US-4870024-A | DILUTION WITH TRIS PHOSPHATE | FISHER SCIENTIFIC COMPANY (US) | 1989-09-26 | — | — | US | disclosed |
| US-4870024-A | DILUTION WITH TRIS PHOSPHATE | FISHER SCIENTIFIC COMPANY (US) | 1989-09-26 | — | — | US | disclosed |
| EP-0304151-A2 | Measurement of calcium ions | INSTRUMENTATION LABORATORY S.p.A. (IT) | 1989-02-22 | — | — | EP | disclosed |
| EP-0304151-A2 | Measurement of calcium ions | INSTRUMENTATION LABORATORY S.p.A. (IT) | 1989-02-22 | — | — | EP | disclosed |
| EP-0029765-B1 | CREATININE IMINOHYDROLASE FREE FROM UREASE ACTIVITY, METHODS OF PREPARATION AND USE, AND ASSAY COMPOSITIONS AND ANALYTICAL ELEMENTS CONTAINING SAME | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1985-05-29 | — | — | EP | disclosed |
| US-4276377-A | AEROBIC CULTURE PRODUCT USED FOR CLINICAL ANALYSIS | EASTMAN KODAK COMPANY (US) | 1981-06-30 | — | — | US | disclosed |
| EP-0029765-A1 | Creatinine iminohydrolase free from urease activity, methods of preparation and use, and assay compositions and analytical elements containing same | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1981-06-03 | — | — | EP | disclosed |
| US-4021198-A | FROM REDUCING AGENT AND COBALT OR NICKEL COMPOUND, COLORIMETRIC ANALYSIS | SANTEN PHARMACEUTICAL CO. LTD. (JA) | 1977-05-03 | — | — | US | disclosed |
| US-4021198-A | FROM REDUCING AGENT AND COBALT OR NICKEL COMPOUND, COLORIMETRIC ANALYSIS | SANTEN PHARMACEUTICAL CO. LTD. (JA) | 1977-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295771-A1 | METHODS AND USES RELATED TO T CELL THERAPY AND PRODUCTION OF SAME | CD2, CD74, PBK | LMNA 1902/4885MEN1 4170/4885KMT2A 358/4885 |
| US-20240342299-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | LMNA 4156/4885MEN1 2331/4885KMT2A 4385/4885 |
| US-20220273613-A1 | COMPOSITION CONTAINING ARTESUNATE | GLS2, GYS2, ACE | LMNA 927/4885MEN1 4173/4885KMT2A 2486/4885 |
| US-20250009710-A1 | COMPOSITION CONTAINING ARTESUNATE | MTAP, PDF, GLS2 | LMNA 1482/4885MEN1 4110/4885KMT2A 3120/4885 |
| US-20090010915-A1 | Methods for Conducting Metabolic Analyses | PC, FAH, CYP27A1 | LMNA 2081/4885MEN1 866/4885KMT2A 3864/4885 |
| US-20250064954-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | LMNA 4156/4885MEN1 2331/4885KMT2A 4385/4885 |
| US-10987338-B2 | Composition containing artesunate | MTAP, PDF, GLS2 | LMNA 1482/4885MEN1 4110/4885KMT2A 3120/4885 |
| US-10471042-B2 | Composition containing artesunate | MTAP, PDF, GLS2 | LMNA 1482/4885MEN1 4110/4885KMT2A 3120/4885 |
| US-12083096-B2 | Composition containing artesunate | GLS2, GYS2, ACE | LMNA 927/4885MEN1 4173/4885KMT2A 2486/4885 |
| US-20260115287-A1 | T CELL THERAPY IN PATIENTS WHO HAVE HAD PRIOR STEM CELL TRANSPLANT | PBK, ICOS, CD47 | LMNA 2799/4885MEN1 896/4885KMT2A 234/4885 |
| US-20220112308-A1 | KRAS SPECIFIC ANTIBODIES AND USES THEREOF | KRAS, NRAS, HRAS | LMNA 4157/4885MEN1 3282/4885KMT2A 2922/4885 |
| US-20190029996-A1 | composition containing artesunate | MTAP, PDF, GLS2 | LMNA 1482/4885MEN1 4110/4885KMT2A 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.